Literature DB >> 26200453

Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.

Sara Pilotto1, Isabella Sperduti2, Silvia Novello3, Umberto Peretti1, Michele Milella4, Francesco Facciolo5, Sabrina Vari4, Giovanni Leuzzi5, Tiziana Vavalà3, Antonio Marchetti6, Felice Mucilli6, Lucio Crinò7, Francesco Puma7, Stefania Kinspergher1, Antonio Santo1, Luisa Carbognin1, Matteo Brunelli8, Marco Chilosi8, Aldo Scarpa9, Giampaolo Tortora1, Emiolio Bria10.   

Abstract

INTRODUCTION: The aim of this analysis (AIRC-MFAG project no. 14282) was to define a risk classification for resected squamous-cell lung cancer based on the combination of clinicopathological predictors to provide a practical tool to evaluate patients' prognosis.
METHODS: Clinicopathological data were retrospectively correlated to disease-free/cancer-specific/overall survival (DFS/CSS/OS) using a Cox model. Individual patient probability was estimated by logistic equation. A continuous score to identify risk classes was derived according to model ratios and dichotomized according to prognosis with receiver operating characteristic analysis.
RESULTS: Data from 573 patients from five institutions were gathered. Four hundred ninety-four patients were evaluable for clinical analysis (median age: 68 years; male/female: 403/91; T-descriptor according to TNM 7th edition 1-2/3-4: 330/164; nodes 0/>0: 339/155; stages I and II/III and IV: 357/137). At multivariate analysis, age, T-descriptor according to TNM 7th edition, nodes, and grading were independent predictors for DFS and OS; the same factors, except age and grading, predicted CSS. Multivariate model predict individual patient probability with high prognostic accuracy (0.67 for DFS). On the basis of receiver operating characteristic-derived cutoff, a two-class model significantly differentiated low-risk and high-risk patients for 3-year DFS (64.6% and 32.4%, p < 0.0001), CSS (84.4% and 44.5%, p < 0.0001), and OS (77.3% and 38.8%, p < 0.0001). A three-class model separated low-risk, intermediate-risk, and high-risk patients for 3-year DFS (64.6%, 39.8%, and 21.8%, p < 0.0001), CSS (84.4%, 55.4%, and 30.9%, p< 0.0001), and OS (77.3%, 47.9%, and 27.2%, p < 0.0001).
CONCLUSIONS: A risk stratification model including often adopted clinicopathological parameters accurately separates resected squamous-cell lung cancer patients into different risk classes. The project is currently ongoing to integrate the clinicopathological model with investigational molecular predictors.

Entities:  

Mesh:

Year:  2015        PMID: 26200453     DOI: 10.1097/JTO.0000000000000628

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.

Authors:  Fidelis Andrea Flockerzi; Cristiana Roggia; Frank Langer; Bernd Holleczek; Rainer M Bohle
Journal:  Virchows Arch       Date:  2017-12-21       Impact factor: 4.064

2.  Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Authors:  Chunji Chen; Yiyang Wang; Xufeng Pan; Shijie Fu; Yubo Shi; Jun Yang; Rui Wang
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

3.  Ideal prognostic model in lung squamous cell carcinoma.

Authors:  Tomonari Kinoshita
Journal:  Transl Lung Cancer Res       Date:  2020-06

4.  Prognostic model based on circular RNA circPDK1 for resected lung squamous cell carcinoma.

Authors:  Xiao Sun; Maolong Wang; Rongjian Xu; Dongyang Zhang; Ao Liu; Yuanyong Wang; Tong Lu; Yanlu Xin; Yandong Zhao; Yunpeng Xuan; Tong Qiu; Hao Wang; Shicheng Li; Yang Wo; Dahai Liu; Jinpeng Zhao; Bo Fu; Yaliang Lan; Yudong Han; Wenjie Jiao
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors.

Authors:  Yiyang Wang; Difan Zheng; Jizhuang Luo; Jie Zhang; Cecilia Pompili; Hideki Ujiie; Natsumi Matsuura; Haiquan Chen; Feng Yao
Journal:  Transl Lung Cancer Res       Date:  2021-05

6.  Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung.

Authors:  Kyowon Gu; Ho Yun Lee; Kyungjong Lee; Joon Young Choi; Sook Young Woo; Insuk Sohn; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

7.  Significantly different immunoscores in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system.

Authors:  Ziqing Zeng; Fan Yang; Yunliang Wang; Hua Zhao; Feng Wei; Peng Zhang; Xiying Zhang; Xiubao Ren
Journal:  Oncoimmunology       Date:  2020-10-07       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.